Interim data show CSF biomarkers of neurodegeneration and synaptic dysfunction as well as neuroimaging biomarkers improved after three months of therapy with XPro1595
Data support initiation of blinded randomized Phase 2 study before year end
Company to host Key Opinion Leader Webinar Today, January 21, at 8:00am ET
To register and access the live webinar click here
Date: January 21, 2021
Time: 8:00 AM Eastern Time
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.